ArticleClinical journal of gastroenterology2026
Cytomegalovirus-induced intrahepatic cholestasis complicated by hemophagocytic syndrome in an immunocompetent adult.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactivation of cytomegalovirus (CMV) remains a significant concern in patients receiving immunosuppressive therapy. Although CMV infection and reactivation is associated with intrahepatic cholestasis in infants and immunosuppressive adults, intrahepatic cholestasis caused by CMV infection is rare in immunocompetent adults. Here, we report a case with CMV-induced intrahepatic cholestasis in an immunocompetent adult complicated by hemophagocytic syndrome (HPS). We excluded CMV infection from differential diagnosis of intrahepatic cholestasis based on serum CMV antibody profiles and immunocompetency at the initial assessment and then started oral administration of prednisolone (PSL). The development of CMV-induced lethal HPS after the treatment with PSL led us to reconsider the possibility of CMV infection as an etiology of cholestasis. Frozen serum before PSL administration exhibited a high copy number of CMV DNA and thus we reached the final diagnosis of CMV-induced intrahepatic cholestasis complicated by HPS. Resolution of cholestasis and HPS was achieved by ganciclovir. The patient exhibited elevated serum levels of IL-18, C-C motif chemokine ligand 2, and IL-13 with no alterations in serum levels of IFN-γ or TNF-α. This case underscores the importance of consideration of CMV reactivation as a differential diagnosis for intrahepatic cholestasis even in immunocompetent patients.
Indexed as
Identifiers
41396402What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.